Poolbeg Pharma has received notification from the European Patent Office confirming the grant of its Immunomodulator II patent application. This approval secures claims covering POLB001 in the treatment of severe influenza, a key area of unmet medical need where the drug’s immunomodulatory mechanism could play a transformative role. The decision further strengthens Poolbeg’s intellectual property estate, adding depth and breadth to the company’s patent portfolio around POLB001. In our view, the ....